Zeitschrift für Blut und Lymphe

Efficacy and Future Prospects of ANK Therapy for ATL, Malignant Lymphoma and Solid Tumors

Abstract

Kenjiro Nagai, Syo Nagai, Yuji Okubo and Keisuke Teshigawara

Amplified Natural Killer Cell (ANK) therapy has been modified to enhance the safety and efficacy of original (LAK) immunotherapy. This is a method of removing Natural Killer (NK) cells from the patient's own blood, culturing and amplifying the NK cells, increasing their ability to specifically attack cancer, and returning them for treatment. It is generally effective against all cancers. Experienced a case in which ANK therapy was remarkably effective against ATL, prostate cancer, and breast cancer. Treatment of ATL is basically chemotherapy, but it is not effective and has many side effects. Chemotherapy is also the main treatment for solid cancer patients whose condition has progressed in the same way, and the elderly, renal failure, and heart failure patients cannot be treated. ANK therapy is highly effective in ATL cases and is also very effective in certain solid tumor cases. Considering the mechanism of action of ANK therapy from the accumulation of cases so far and research reports so far, it is effective for ATL with many PD positive tumor cells because it effectively kills PD-L1 positive tumor cells. Some types of solid tumors, such as lymphoma, gastric cancer, lung cancer, breast cancer, and prostate cancer, have many PD-L1-positive tumor cells. By measuring PD-L1-positive tumor cells and treating those with high levels, it may be possible to provide treatments that are more effective, have fewer side effects, and are safer than existing treatments.